PedAM
Pediatric Disease Annotations & Medicines
| dermatomyositis | ||||
| Disease ID | 66 |
|---|---|
| Disease | dermatomyositis |
| Manually Symptom | UMLS | Name(Total Manually Symptoms:153) C2700478 | meningioma C2697424 | gastric cancer C2697391 | rheumatoid arthritis C2364133 | infection C2242539 | subcutaneous infection C1963274 | vasculitis C1963235 | sick sinus syndrome C1963220 | pulmonary hypertension C1963198 | pancreatitis C1963164 | lymphopenia C1963154 | renal failure C1963079 | restrictive cardiomyopathy C1962966 | retinopathy C1961102 | acute lymphoblastic leukemia C1959600 | endomyocardial fibrosis C1956346 | coronary artery disease C1704251 | lymphoma of the breast C1696156 | pharyngeal necrosis C1402315 | vascular lesions C1377913 | pleural mesothelioma C1333789 | squamous cell carcinoma of the stomach C1322286 | thymic carcinoma C1302772 | cutaneous lymphoma C1290344 | nonspecific interstitial pneumonia C1279945 | acute interstitial pneumonia C1262241 | gastric melanoma C1253937 | pericardial effusion C1145670 | respiratory failure C1140680 | ovarian cancer C1112565 | pneumatosis intestinalis C1096584 | chlamydia pneumoniae infection C1090821 | sepsis C1027109 | scleroderma C0947912 | myasthenia C0919642 | ureteral necrosis C0878544 | myocardiopathies C0751378 | neurologic signs C0748355 | acute respiratory distress C0748214 | epidermoid carcinoma of the pyriform sinus C0748159 | pulmonary involvement C0744422 | diffuse proliferative glomerulonephritis C0741949 | cardiovascular pathology C0740577 | acute abdominal pain C0699791 | gastric carcinoma C0678222 | breast carcinoma C0600139 | carcinoma of the prostate C0547058 | pseudopolyposis C0522224 | palsy C0520473 | organic psychosis C0473120 | abdominal hematoma C0410000 | overlap syndrome C0406650 | linear iga bullous dermatosis C0334663 | true histiocytic lymphoma C0334419 | malignant pheochromocytoma C0311343 | membranous conjunctivitis C0278584 | metastatic carcinoma of the cervix C0272126 | evans' syndrome C0267373 | intestinal haemorrhage C0267356 | duodenal perforation C0267063 | cricopharyngeal achalasia C0263627 | calcinosis universalis C0263367 | koebner phenomenon C0262988 | cutaneous vasculitis C0262941 | myofasciitis C0242770 | bronchiolitis obliterans organizing pneumonia C0242584 | autoimmune thrombocytopenia C0240035 | interstitial pulmonary fibrosis C0239946 | liver fibrosis C0238301 | nasopharyngeal carcinoma C0238301 | nasopharyngeal cancer C0238265 | marchiafava-bignami disease C0238115 | spontaneous rupture of esophagus C0221011 | malignant atrophic papulosis C0206698 | cholangiocarcinoma C0206695 | neuroendocrine carcinoma C0206178 | cytomegalovirus retinitis C0206178 | cmv retinitis C0206062 | interstitial lung disease C0206061 | interstitial pneumonitis C0206061 | interstitial pneumonia C0162855 | mucinosis C0162839 | porokeratosis C0155765 | microangiopathy C0155320 | cortical blindness C0153619 | ureteral cancer C0151436 | cutaneous leukocytoclastic vasculitis C0149871 | deep venous thrombosis C0085652 | pyoderma gangrenosum C0079772 | t-cell lymphoma C0079772 | t cell lymphoma C0079731 | b-cell lymphoma C0042769 | virus infection C0041834 | erythema C0041296 | tuberculosis C0040188 | tic disorders C0040034 | thrombocytopenia C0039103 | synovitis C0037285 | skin manifestations C0037285 | skin manifestation C0037284 | skin lesions C0037284 | skin lesion C0037274 | skin disease C0036262 | scabies C0036220 | kaposi's sarcoma C0035333 | retinitis C0034069 | pulmonary fibrosis C0034067 | emphysema C0033860 | psoriasis C0033771 | prurigo C0032266 | pneumatosis cystoides intestinalis C0030805 | bullous pemphigoid C0030781 | peliosis hepatis C0030436 | parakeratosis C0030326 | panniculitis C0029166 | oral manifestations C0029132 | optic neuropathy C0029089 | ophthalmoplegia C0027947 | neutropenia C0027051 | myocardial infarction C0026848 | myopathy C0026764 | multiple myeloma C0025517 | metabolism disorders C0024305 | non-hodgkin's lymphoma C0024299 | lymphoma C0024291 | hemophagocytic syndrome C0024291 | haemophagocytic syndrome C0023524 | progressive multifocal leukoencephalopathy C0022660 | acute renal failure C0021845 | intestinal perforation C0020758 | ichthyosis C0018799 | heart disease C0018799 | diseases of the heart C0017665 | membranous nephropathy C0017658 | glomerulonephritis C0015970 | fever of unknown origin C0015645 | fasciitis C0015230 | skin rash C0015230 | skin eruption C0015230 | rashes C0015230 | rash C0011168 | dysphagia C0009782 | connective tissue disease C0007286 | carpal tunnel syndrome C0007138 | transitional cell carcinoma C0006664 | calcinosis cutis C0006663 | calcinosis C0005742 | blepharochalasis C0003864 | arthritides C0002991 | dermatofibromas C0002880 | autoimmune haemolytic anaemia C0002726 | amyloidosis C0001815 | idiopathic myelofibrosis C0000889 | acanthosis nigricans |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:33) C0206062 | interstitial lung disease | 25 C0206061 | interstitial pneumonia | 13 C0006663 | calcinosis | 8 C0003873 | rheumatoid arthritis | 5 C0009450 | infection | 5 C0238301 | nasopharyngeal carcinoma | 4 C0042384 | vasculitis | 4 C0410000 | overlap syndrome | 4 C0030326 | panniculitis | 3 C0006664 | calcinosis cutis | 2 C1279945 | acute interstitial pneumonia | 2 C0015230 | rash | 2 C0011644 | scleroderma | 2 C0017658 | glomerulonephritis | 1 C0041834 | erythema | 1 C0034069 | pulmonary fibrosis | 1 C0042769 | virus infection | 1 C0263627 | calcinosis universalis | 1 C0024623 | gastric cancer | 1 C0947912 | myasthenia | 1 C0024299 | lymphoma | 1 C0206698 | cholangiocarcinoma | 1 C0040034 | thrombocytopenia | 1 C0155765 | microangiopathy | 1 C0009782 | connective tissue disease | 1 C0015230 | skin rash | 1 C0035309 | retinopathy | 1 C0011168 | dysphagia | 1 C0153392 | nasopharyngeal cancer | 1 C0744422 | diffuse proliferative glomerulonephritis | 1 C0037285 | skin manifestations | 1 C1140680 | ovarian cancer | 1 C0037284 | skin lesion | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:12) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs10069690 | 26320593 | 7015 | TERT | umls:C0011633 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.000271442 | 2015 | TERT | 5 | 1279675 | C | T |
| rs10069690 | 26320593 | 6366 | CCL21 | umls:C0011633 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.002995792 | 2015 | TERT | 5 | 1279675 | C | T |
| rs11171739 | 26320593 | 7015 | TERT | umls:C0011633 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.000271442 | 2015 | NA | 12 | 56076841 | C | T |
| rs11171739 | 26320593 | 6366 | CCL21 | umls:C0011633 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.002995792 | 2015 | NA | 12 | 56076841 | C | T |
| rs2292239 | 26320593 | 7015 | TERT | umls:C0011633 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.000271442 | 2015 | ERBB3 | 12 | 56088396 | T | G |
| rs2292239 | 26320593 | 6366 | CCL21 | umls:C0011633 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.002995792 | 2015 | ERBB3 | 12 | 56088396 | T | G |
| rs2492358 | 26320593 | 7015 | TERT | umls:C0011633 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.000271442 | 2015 | NA | 9 | 34737831 | C | T |
| rs2492358 | 26320593 | 6366 | CCL21 | umls:C0011633 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.002995792 | 2015 | NA | 9 | 34737831 | C | T |
| rs2853676 | 26320593 | 6366 | CCL21 | umls:C0011633 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.002995792 | 2015 | TERT | 5 | 1288432 | T | C |
| rs2853676 | 26320593 | 7015 | TERT | umls:C0011633 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.000271442 | 2015 | TERT | 5 | 1288432 | T | C |
| rs951005 | 26320593 | 6366 | CCL21 | umls:C0011633 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.002995792 | 2015 | NA | 9 | 34743684 | G | A |
| rs951005 | 26320593 | 7015 | TERT | umls:C0011633 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.000271442 | 2015 | NA | 9 | 34743684 | G | A |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:6) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CHR | POS | SNPID | REF | ALT | ORI_SNPID | PMID | P_VALUE | P_VALUE_TEXT | OR/BETA | CI95_TEXT | GWAS_INITIAL_SAMPLE_SIZE | SUB_POPULATION | SUPER_POPULATION | GWAS_TRAIT | HPO_ID | HPO_TERM | DO_ID | DO_TERM | MESH_ID | MESH_TERM | EFO_ID | EFO_TERM | DOLITE_TERM | RISK_ALLELE | PUBLICATION_TYPE | AA | GENE_SYMBOL | TYPE | REFGENE |
| 2 | 198780860 | rs938929 | A | G | rs938929 | 23983088 | 8.32E-05 | NA | 1.22 | [1.10-1.34] | 1,178 European ancestry cases; 4,724 European ancestry controls | European(5902) | ALL(5902) | EUR(5902) | ALL(5902) | Dermatomyositis | HPOID:0100614 | HPOID:0010978 | Myositis | Abnormality of immune system physiology | DOID:10223 | dermatomyositis | NA | NA | NA | NA | Polymyositis | NA | Research Support, Non-U.S. Gov't |
| 2 | 198809975 | rs1518364 | G | A | rs1518364 | 23983088 | 5.11E-05 | NA | 1.22 | [1.11-1.35] | 1,178 European ancestry cases; 4,724 European ancestry controls | European(5902) | ALL(5902) | EUR(5902) | ALL(5902) | Dermatomyositis | HPOID:0100614 | HPOID:0010978 | Myositis | Abnormality of immune system physiology | DOID:10223 | dermatomyositis | NA | NA | NA | NA | Polymyositis | NA | Research Support, Non-U.S. Gov't |
| 2 | 198929806 | rs7572733 | C | T | rs7572733 | 23983088 | 6.00E-06 | NA | 1.25 | [1.14-1.39] | 1,178 European ancestry cases; 4,724 European ancestry controls | European(5902) | ALL(5902) | EUR(5902) | ALL(5902) | Dermatomyositis | HPOID:0100614 | HPOID:0010978 | Myositis | Abnormality of immune system physiology | DOID:10223 | dermatomyositis | NA | NA | NA | NA | Polymyositis | NA | Research Support, Non-U.S. Gov't |
| 8 | 11343973 | rs2736340 | C | T | rs2736340 | 23983088 | 6.53E-05 | NA | 1.25 | [1.12-1.40] | 1,178 European ancestry cases; 4,724 European ancestry controls | European(5902) | ALL(5902) | EUR(5902) | ALL(5902) | Dermatomyositis | HPOID:0100614 | HPOID:0010978 | Myositis | Abnormality of immune system physiology | DOID:10223 | dermatomyositis | NA | NA | NA | NA | Polymyositis | NA | Research Support, Non-U.S. Gov't |
| 9 | 34737828 | rs2492358 | C | T | rs2492358 | 23983088 | 2.09E-04 | NA | 1.3 | [1.14-1.49] | 1,178 European ancestry cases; 4,724 European ancestry controls | European(5902) | ALL(5902) | EUR(5902) | ALL(5902) | Dermatomyositis | HPOID:0100614 | HPOID:0010978 | Myositis | Abnormality of immune system physiology | DOID:10223 | dermatomyositis | NA | NA | NA | NA | Polymyositis | NA | Research Support, Non-U.S. Gov't |
| 9 | 34743681 | rs951005 | G | A | rs951005 | 23983088 | 3.17E-04 | NA | 1.3 | [1.12-1.49] | 1,178 European ancestry cases; 4,724 European ancestry controls | European(5902) | ALL(5902) | EUR(5902) | ALL(5902) | Dermatomyositis | HPOID:0100614 | HPOID:0010978 | Myositis | Abnormality of immune system physiology | DOID:10223 | dermatomyositis | NA | NA | NA | NA | Polymyositis | NA | Research Support, Non-U.S. Gov't |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:9) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0011633 | cyclophosphamide | D003520 | 50-18-0 | dermatomyositis | MESH:D003882 | marker/mechanism | 12492978 | ||
| C0011633 | diclofenac | D004008 | 15307-86-5 | dermatomyositis | MESH:D003882 | marker/mechanism | 2917682 | ||
| C0011633 | fluorouracil | D005472 | 51-21-8 | dermatomyositis | MESH:D003882 | marker/mechanism | 18424388 | ||
| C0011633 | hydroxyurea | D006918 | 127-07-1 | dermatomyositis | MESH:D003882 | marker/mechanism | 18625537 | ||
| C0011633 | lovastatin | D008148 | 75330-75-5 | dermatomyositis | MESH:D003882 | marker/mechanism | 8944218 | ||
| C0011633 | methotrexate | D008727 | 1959/5/2 | dermatomyositis | MESH:D003882 | therapeutic | 20191521 | ||
| C0011633 | omeprazole | D009853 | 73590-58-6 | dermatomyositis | MESH:D003882 | marker/mechanism | 16445794 | ||
| C0011633 | phenytoin | D010672 | 57-41-0 | dermatomyositis | MESH:D003882 | marker/mechanism | 9853654 | ||
| C0011633 | pravastatin | D017035 | 81093-37-0 | dermatomyositis | MESH:D003882 | marker/mechanism | 16154665 | ||
FDA approved drug and dosage information(Total Drugs:5) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D003882 | mevacor | lovastatin | 10MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | TABLET;ORAL | Discontinued | None | Yes | No |
| MESH:D003882 | prilosec | omeprazole | 20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | CAPSULE, DELAYED REL PELLETS;ORAL | Discontinued | None | Yes | No |
| MESH:D003882 | prilosec | omeprazole | 20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | CAPSULE, DELAYED REL PELLETS;ORAL | Discontinued | None | Yes | No |
| MESH:D003882 | omeprazole | omeprazole | 20MG | TABLET, DELAYED RELEASE;ORAL | Over-the-counter | None | Yes | Yes |
| MESH:D003882 | omeprazole | omeprazole | 20MG | TABLET, DELAYED RELEASE;ORAL | Over-the-counter | None | Yes | Yes |
FDA labeling changes(Total Drugs:5) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D003882 | 02/14/2002 | mevacor | lovastatin | Heterozygous Familial Hypercholesterolemia | New indication in adolescent boys and girls (at least one year post-menarche) 10-17 years of age | Labeling | B | - | - | - | Merck | 07/17/2001 | FALSE' |
| MESH:D003882 | 12/7/2002 | prilosec | omeprazole | Gastroesophageal reflux and erosive esophagitis | Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile | Labeling | B | - | - | - | AstraZeneca | - | FALSE' |
| MESH:D003882 | 03/20/2008 | prilosec | omeprazole | Maintenance healing of erosive esophagitis | Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form | Labeling | - | - | B, P | - | AstraZeneca | 1/5/2001 | FALSE' |
| MESH:D003882 | 12/7/2002 | prilosec | omeprazole | Gastroesophageal reflux and erosive esophagitis | Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile | Labeling | B | - | - | - | AstraZeneca | - | FALSE' |
| MESH:D003882 | 03/20/2008 | prilosec | omeprazole | Maintenance healing of erosive esophagitis | Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form | Labeling | - | - | B, P | - | AstraZeneca | 1/5/2001 | FALSE' |